[Funding alert] London-based Evaro Secures $1.5Million in Seed Funding

With the money, the business will expand into the B2B sector by developing a plug-and-play solution that would enable consumer brands to give their clients managed prescription services. With the funds, Evaro will be able to provide 2,000 treatments instead of just 200, covering 70% of the minor health conditions that NHS doctors generally treat.

Read also -  Netherlands-based Tidal Control Secures €500K in a Pre-Seed Round Funding

The organization also hopes to obtain a treatment Quality Commission (CQC) license, which would allow for more thorough patient treatment, including the beginning of therapy and diagnosis.

Evaro is a medical startup founded in 2018 by Thuria and Oskar Wenbar. It offers access to private prescription drugs and AI-driven asynchronous consultations through a machine learning and artificial intelligence model based on 13.5 million patient records.

Read also - Limburg-based Foodtech Company Verdify Raises €2.4Million in Funding

Additionally, it employs a strict, legally compliant patient safety procedure wherein requests for online treatment are subject to an asynchronous consultation, with safeguards in place to identify manipulated answers, and drug orders are examined for appropriate dosages and quantities, with GP alerts provided as needed.

About Evaro

With only one line of code, they allow brands to easily incorporate prescription medicine services into their product offers. For forward-thinking companies wishing to get into the digital health market, Evaro offers a turnkey solution. The technology, compliance, and fulfillment from their warehouse pharmacy and aftercare are managed by Evaro.

Read also - Amsterdam-based Send AI Raises €2.2Million in a Pre-Seed Round Funding